Non-small cell lung cancer: Emerging molecular targeted and immunotherapeutic agents
T Singh, MF Hassanabad, AF Hassanabad - Biochimica et Biophysica Acta …, 2021 - Elsevier
Non-small cell lung cancer (NSCLC) represents the most common and fatal type of primary
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic therapies…
lung malignancies. NSCLC is often diagnosed at later stages and requires systemic therapies…
Clinical performance of the Abbott Panbio with nasopharyngeal, throat, and saliva swabs among symptomatic individuals with COVID-19
…, D Portnoy, B Scott, J Szelewicki, T Singh… - European Journal of …, 2021 - Springer
SARS-CoV-2 antigen tests used at the point-of-care, such as the Abbott Panbio, have great
potential to help combat the COVID-19 pandemic. The Panbio is Health Canada approved …
potential to help combat the COVID-19 pandemic. The Panbio is Health Canada approved …
Saliva collected in universal transport media is an effective, simple and high-volume amenable method to detect SARS-CoV-2
…, AR Schneider, T Singh… - Clinical …, 2021 - clinicalmicrobiologyandinfection …
During the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Co-V-2) pandemic
we have encountered unprecedented testing volumes and constant supply chain disruptions, …
we have encountered unprecedented testing volumes and constant supply chain disruptions, …
Acceptable performance of the Abbott ID NOW among symptomatic individuals with confirmed COVID-19
W Stokes, BM Berenger, T Singh… - Journal of Medical …, 2021 - microbiologyresearch.org
Introduction. The ID NOW is FDA approved for the detection of SARS-CoV-2 in symptomatic
individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of …
individuals within the first 7 days of symptom onset for COVID-19 if tested within 1 h of …
We Asked the experts: the WHO surgical safety checklist and the COVID‐19 pandemic: recommendations for content and implementation adaptations
N Panda, JC Etheridge, T Singh… - World Journal of …, 2021 - Wiley Online Library
Background As surgical systems are forced to adapt and respond to new challenges, so should
the patient safety tools within those systems. We sought to determine how the WHO SSC …
the patient safety tools within those systems. We sought to determine how the WHO SSC …
One swab fits all: performance of a rapid, antigen-based SARS-CoV-2 test using a nasal swab, nasopharyngeal swab for nasal collection, and RT–PCR confirmation …
…, B Scott, J Szelewicki, T Singh… - The Journal of …, 2022 - academic.oup.com
Background Point-of-care SARS-CoV-2 antigen tests have great potential to help combat
the COVID-19 pandemic. In the performance of a rapid, antigen-based SARS-CoV-2 test (RAT)…
the COVID-19 pandemic. In the performance of a rapid, antigen-based SARS-CoV-2 test (RAT)…
Real-world clinical performance of the Abbott Panbio with nasopharyngeal, throat and saliva swabs among symptomatic individuals with COVID-19
…, D Portnoy, B Scott, J Szelewicki, T Singh… - medRxiv, 2021 - medrxiv.org
BACKGROUND Point of Care Testing (POCT) SARS-CoV-2 antigen tests, such as the Abbott
Panbio, have great potential to help combat the COVID-19 pandemic. The Panbio is United …
Panbio, have great potential to help combat the COVID-19 pandemic. The Panbio is United …
Acceptable Performance of the Abbott ID NOW Among Symptomatic Individuals with Confirmed COVID-19 (preprint)
W Stokes, B Berenger, T Singh, I Adeghe, A Schneider… - 2020 - pesquisa.bvsalud.org
INTRODUCTION Point of care diagnostic tests for SARS-CoV-2, such as the ID NOW, have
great potential to help combat the COVID-19 pandemic. The ID NOW is approved by the …
great potential to help combat the COVID-19 pandemic. The ID NOW is approved by the …
